144 related articles for article (PubMed ID: 29796729)
1. Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
Torrejón B; Cristóbal I; Caramés C; Prieto-Potín I; Chamizo C; Santos A; Sanz-Alvarez M; Serna-Blasco R; Luque M; Madoz-Gúrpide J; Rojo F; García-Foncillas J
World J Surg; 2018 Nov; 42(11):3771-3778. PubMed ID: 29796729
[TBL] [Abstract][Full Text] [Related]
2. TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer.
Qiao HY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Yan J; Li C; Wang HQ
Cancer Lett; 2022 Mar; 529():85-99. PubMed ID: 34973391
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.
Cristóbal I; Rincón R; Manso R; Caramés C; Zazo S; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Clin Cancer Res; 2015 Jan; 21(2):347-56. PubMed ID: 25388166
[TBL] [Abstract][Full Text] [Related]
5. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
Piazza R; Valletta S; Winkelmann N; Redaelli S; Spinelli R; Pirola A; Antolini L; Mologni L; Donadoni C; Papaemmanuil E; Schnittger S; Kim DW; Boultwood J; Rossi F; Gaipa G; De Martini GP; di Celle PF; Jang HG; Fantin V; Bignell GR; Magistroni V; Haferlach T; Pogliani EM; Campbell PJ; Chase AJ; Tapper WJ; Cross NC; Gambacorti-Passerini C
Nat Genet; 2013 Jan; 45(1):18-24. PubMed ID: 23222956
[TBL] [Abstract][Full Text] [Related]
6. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
[TBL] [Abstract][Full Text] [Related]
7. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.
Cristóbal I; Blanco FJ; Garcia-Orti L; Marcotegui N; Vicente C; Rifon J; Novo FJ; Bandres E; Calasanz MJ; Bernabeu C; Odero MD
Blood; 2010 Jan; 115(3):615-25. PubMed ID: 19965692
[TBL] [Abstract][Full Text] [Related]
8. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.
Cristóbal I; Rincón R; Manso R; Madoz-Gúrpide J; Caramés C; del Puerto-Nevado L; Rojo F; García-Foncillas J
Biochim Biophys Acta; 2014 Sep; 1842(9):1823-9. PubMed ID: 24997451
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Cristóbal I; Garcia-Orti L; Cirauqui C; Cortes-Lavaud X; García-Sánchez MA; Calasanz MJ; Odero MD
Haematologica; 2012 Apr; 97(4):543-50. PubMed ID: 22133779
[TBL] [Abstract][Full Text] [Related]
10. The B56γ3-containing protein phosphatase 2A attenuates p70S6K-mediated negative feedback loop to enhance AKT-facilitated epithelial-mesenchymal transition in colorectal cancer.
Hsiao KC; Ruan SY; Chen SM; Lai TY; Chan RH; Zhang YM; Chu CA; Cheng HC; Tsai HW; Tu YF; Law BK; Chang TT; Chow NH; Chiang CW
Cell Commun Signal; 2023 Jul; 21(1):172. PubMed ID: 37430297
[TBL] [Abstract][Full Text] [Related]
11. The protein level of the tumour-promoting factor SET is regulated by cell density.
Kohyanagi N; Kitamura N; Tanaka K; Mizuno T; Fujiwara N; Ohama T; Sato K
J Biochem; 2022 Mar; 171(3):295-303. PubMed ID: 35076073
[TBL] [Abstract][Full Text] [Related]
12. The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells.
Trotta R; Ciarlariello D; Dal Col J; Mao H; Chen L; Briercheck E; Yu J; Zhang J; Perrotti D; Caligiuri MA
Blood; 2011 Feb; 117(8):2378-84. PubMed ID: 21156847
[TBL] [Abstract][Full Text] [Related]
13. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
14. Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.
Acuna-Hidalgo R; Deriziotis P; Steehouwer M; Gilissen C; Graham SA; van Dam S; Hoover-Fong J; Telegrafi AB; Destree A; Smigiel R; Lambie LA; Kayserili H; Altunoglu U; Lapi E; Uzielli ML; Aracena M; Nur BG; Mihci E; Moreira LM; Borges Ferreira V; Horovitz DD; da Rocha KM; Jezela-Stanek A; Brooks AS; Reutter H; Cohen JS; Fatemi A; Smitka M; Grebe TA; Di Donato N; Deshpande C; Vandersteen A; Marques Lourenço C; Dufke A; Rossier E; Andre G; Baumer A; Spencer C; McGaughran J; Franke L; Veltman JA; De Vries BB; Schinzel A; Fisher SE; Hoischen A; van Bon BW
PLoS Genet; 2017 Mar; 13(3):e1006683. PubMed ID: 28346496
[TBL] [Abstract][Full Text] [Related]
15. The role of c2orf68 and PI3K/Akt/mTOR pathway in human colorectal cancer.
Wen X; Zhu J; Dong L; Chen Y
Med Oncol; 2014 Aug; 31(8):92. PubMed ID: 25023051
[TBL] [Abstract][Full Text] [Related]
16. The impact of SETBP1 mutations in neurological diseases and cancer.
Kohyanagi N; Ohama T
Genes Cells; 2023 Sep; 28(9):629-641. PubMed ID: 37489294
[TBL] [Abstract][Full Text] [Related]
17. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A.
Irie A; Harada K; Araki N; Nishimura Y
PLoS One; 2012; 7(12):e51242. PubMed ID: 23251465
[TBL] [Abstract][Full Text] [Related]
19. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
[TBL] [Abstract][Full Text] [Related]
20. PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers.
Tamaki M; Goi T; Hirono Y; Katayama K; Yamaguchi A
Oncol Rep; 2004 Mar; 11(3):655-9. PubMed ID: 14767517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
